Related Experiment Video
Updated: Apr 25, 2026
04:41
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
7.9K
Genetic polymorphisms in preoperative myocardial infarction
Sefa Senol1, Mehmet Ugur Es2, Gökhan Gokmen3
1Department of Cardiovascular Surgery, Educational and Research Hospital, Elazig, Turkey ssenol2012@gmail.com.
Asian Cardiovascular & Thoracic Annals
|August 15, 2014
Summary
Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene polymorphisms were not associated with myocardial infarction with ST-segment elevation in patients undergoing coronary artery bypass grafting. These genetic factors did not prove to be risk factors in the studied population.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Thrombosis Research
Background:
- Myocardial infarction with ST-segment elevation (STEMI) is a critical cardiovascular event.
- Coronary artery bypass grafting (CABG) is a common revascularization strategy for STEMI.
- Genetic predispositions are increasingly investigated for cardiovascular disease risk.
Purpose of the Study:
- To investigate the association of plasminogen activator inhibitor 1 (PAI-1) and methylenetetrahydrofolate reductase (MTHFR) polymorphisms with STEMI.
- To compare PAI-1 and MTHFR C677T and A1298C allele frequencies in STEMI patients before CABG versus controls with prior CABG.
Main Methods:
- Real-time polymerase chain reaction (PCR) was used to determine genetic polymorphisms.
- A study group comprised 70 STEMI patients scheduled for CABG.
- A control group consisted of 70 patients with a history of CABG.
Main Results:
- No significant differences were observed in PAI-1 polymorphisms between the groups.
- MTHFR C677T and A1298C polymorphisms showed no significant differences between STEMI patients and controls.
- Allele frequencies for both PAI-1 and MTHFR polymorphisms were comparable between the two groups.
Conclusions:
- PAI-1 and MTHFR gene polymorphisms are not associated with STEMI in patients undergoing CABG.
- These specific genetic variations do not appear to be risk factors for STEMI in this patient cohort.
- Further research may explore other genetic markers in relation to STEMI and CABG outcomes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
01:27Principles of Pharmacogenetics: Types of Genetic Variants
135
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
328
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
328